Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly, Daiichi Sankyo Suspend Enrollment In Phase II Trials Of Prasugrel

This article was originally published in The Pink Sheet Daily

Executive Summary

Analysis of “a number of studies” underlies decision to temporarily suspend enrollment to consider dosing changes for the anti-platelet therapy, Lilly tells “The Pink Sheet” DAILY.

You may also be interested in...



Lilly’s Prasugrel Superior To Bristol’s Plavix In Reducing CV Events In Pivotal TRITON Trial

Efficacy tempered by an increase in non-CABG bleeding compared to clopidogrel.

Lilly’s Prasugrel Superior To Bristol’s Plavix In Reducing CV Events In Pivotal TRITON Trial

Efficacy tempered by an increase in non-CABG bleeding compared to clopidogrel.

Bristol Halts Development Of Vinflunine In Bladder Cancer

Company is in discussions with FDA regarding novel cytotoxic, but does not expect to file an NDA for bladder cancer; vinflunine program also includes lung and breast cancer studies.

Related Content

Topics

UsernamePublicRestriction

Register

OM006665

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel